Fibrosure test. The results of these assays are factored together, along with patient Noninvasive assessment of liver fibrosis and necroinflammatory activity for patients with HCV HCV FibroSure® is a noninvasive blood test of 6 biochemical markers that provides METAVIR fibrosis staging and necroinflammatory grading. Order the test now. BioPredictive is an independent bio-pharmaceutical company, based in France, which designs and markets diagnostic tests for liver diseases, in particular FibroTest and NASH-FibroTest. Individual results from the 10 component tests are also provided with institution-specific reference intervals. The FibroSure® test is an algorithm-based test that provides scores for fibrosis, steatosis and NASH based on the results obtained for several blood markers. Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of adults in developed countries. 2 Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease Aug 12, 2025 · FIB-4 should be used as the first-line non-invasive test for liver fibrosis assessment in all patients with suspected NAFLD, while FibroSure (proprietary tes This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). An additional component – alanine aminotransferase (ALT) – is infrequently used to test for necroinflammatory lesions. Necessary Information Age and sex are required. This addition is known as ActiTest. NASH FibroSure® Plus is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). It has the same prognostic value as a liver biopsy and can be used for various liver diseases. Specimen Required Oct 28, 2025 · The FibroSure® test is an algorithm-based test that provides scores for fibrosis, steatosis and NASH based on the results obtained for several blood markers. Aug 12, 2025 · When to Order FIB-4 vs. Testing will be canceled if a specimen is received from a patient in this age group. Scores based on laboratory values and demographic variables have been developed and validated for assessing fibrosis in patients with hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD), as have several imaging methods that measure shear-wave . HCV FibroSure has been validated against liver biopsy in multiple studies,1-3 and has demonstrated diagnostic value comparable to liver biopsy in assessing fibrosis. The NASH Fibrosure Plus is a more streamlined testing process that looks into the status of your liver. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 NAFLD Fibrosis Score - The NAFLD fibrosis score is a simple noninvasive approach to identify patients that may have significant liver fibrosis and who therefore might benefit from additional studies such as elastography or liver biopsy. 0, S0-S3) and nonalcoholic Mar 16, 2024 · FibroTest and ActiTest The HCV FibroTest and ActiTest are used for the assessment of liver fibrosis and inflammation, respectively. This test provides numeric scores that assess hepatic fibrosis (FibroTest), hepatic inflammation (NashTest 2), and steatosis (SteatoTest 2). Oct 27, 2025 · FibroSURE is a patented algorithm that uses six or ten serum markers to estimate the stage and grade of liver fibrosis and inflammation in patients with hepatitis C, NASH or other chronic liver diseases. Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0. FibroTest: The FibroTest uses a proprietary algorithm that includes the individual’s age and sex, along with a composite of five biochemical markers associated with hepatic fibrosis: alpha-2-macroglobulin, haptoglobin, gamma-glutamyltransferase (GGT FibroSURE is a combination of five biochemical assays: alpha2-macroglobulin, haptoglobulin, apolipoprotein A1, gamma glutamyl transpeptidase (GGT) and total bilirubin. Interpretation of the scores is provided in the report. Clinical Significance Liver Fibrosis, FibroTest-ActiTest Panel - FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. No doctor or insurance needed. FibroSure Tests in Outpatient GI Practice FIB-4 should be used as the first-line non-invasive test for liver fibrosis assessment in all patients with suspected NAFLD, while FibroSure (proprietary test) should be reserved for second-tier testing in patients with indeterminate FIB-4 results. 1 Test ID: NSFIB Nonalcoholic Steatohepatitis (NASH)-FibroTest, Serum and Plasma Ordering Guidance This test is not offered for patients younger than 14 years of age. The test is marketed by LabCorp, but it is not approved by FDA and it is not recommended by evidence-based guidelines. 0, S0-S3), and nonalcoholic steatohepatitis (NASH Dec 1, 2025 · Overview of noninvasive methods for assessing hepatic fibrosis, including serologic tests and imaging examinations. 0-1. 0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0. It is associated with obesity, diabetes, and dyslipidemia Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Mar 1, 2019 · Staging of liver fibrosis is increasingly done using noninvasive methods, in some cases obviating the need for liver biopsy. However, if any of these markers are unusually high or low, the FibroSure® algorithm may not be able to calculate one or more of the scores accurately. FibroTest, also known as FibroSure in the US, is a blood test that measures six serum markers and calculates a score correlated with the degree of liver fibrosis and inflammation. zbebc wapkrh mecz uvj lke qpuij mpjx mhsq wpllul ktx